The murine model of acquired immunodeficiency disease was used to evaluate both the antiretroviral and antiherpetic activities of the acyclic nucleotide analog 9-(2-phosphonylmethoxyethyl)adenine (PMEA). The antiretroviral activity of PMEA was compared with that of azidothymidine (AZT) in mice receiving the drug either immediately after infection or at late times in disease progression. Both AZT (oral, Infection of C57BL/6 mice with the LP-BM5 retrovirus complex causes an AIDS-like disease, murine AIDS (MAIDS), the pathology of which at least partially resembles that of human AIDS (14, 17, 18, 22) . Because of the similarities to human AIDS and the ease with which disease manifestations can be measured, the MAIDS model provides a safe and inexpensive means with which to evaluate the in vivo efficacy of antiretroviral agents and other agents that may be useful in the treatment of opportunistic infections. Moreover, this model could be used to establish a base from which therapeutic strategies to be employed in other more costly feline and primate models could be designed.
The discovery and development of drugs effective against the human immunodeficiency virus or against the opportunistic pathogens commonly associated with acquired immunodeficiency syndrome (AIDS) is made difficult by the lack of suitable and convenient animal models. Several conventional murine retrovirus models such as Friend, Rauscher, and Moloney leukemia are currently used to determine the in vivo efficacy of new antiviral agents. Although these animal models are useful in measuring the ability of a drug to prevent or suppress retrovirus replication, they tell us little about its ability to prevent or suppress the development of virus-induced immunosuppression and susceptibility to opportunistic infections.
Infection of C57BL/6 mice with the LP-BM5 retrovirus complex causes an AIDS-like disease, murine AIDS (MAIDS), the pathology of which at least partially resembles that of human AIDS (14, 17, 18, 22) . Because of the similarities to human AIDS and the ease with which disease manifestations can be measured, the MAIDS model provides a safe and inexpensive means with which to evaluate the in vivo efficacy of antiretroviral agents and other agents that may be useful in the treatment of opportunistic infections. Moreover, this model could be used to establish a base from which therapeutic strategies to be employed in other more costly feline and primate models could be designed.
A number of 3-hydroxy-2-phosphonylmethoxypropyl (HPMP) and 2-phosphonylmethoxyethyl (PME) derivatives of purine and pyrimidine have been evaluated for their antiviral properties (1, [5] [6] [7] 13) . In general, HPMP analogs * Corresponding author.
are more active than PME compounds against vaccinia virus, adenovirus, cytomegalovirus, and varicella-zoster virus. In contrast, PME analogs are more effective than HPMP analogs against the human immunodeficiency virus. Nonetheless, HPMP and PME analogs are equally effective against herpes simplex viruses (HSV).
Because of their broad-spectrum activity against DNA viruses and retroviruses, both HPMP and PME analogs offer a wealth of potential applications, particularly in the treat (10-12, 14, 17, 18) .
A nonneurovirulent strain (VR3) of HSV-1 was obtained from the laboratory of A. Nahmias (Emory University, Atlanta, Ga.) and propagated in Vero cells. Virus stocks contained 2.5 x 107 PFU/ml and were stored at -80°C.
Complete descriptions of this virus and the marine model of pneumonitis that is induced in young (4-week-old) mice after intranasal instillation have been reported elsewhere (9, 20) (19) is based on the ability of the dehydrogenases present in the mitochondria of living cells to cleave the tetrazolium ring of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide. Briefly, 2 x 105 splenocytes were cultured for 48 h in the presence of 4 jig of ConA. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide was then added, and the products of cleavage were determined colorimetrically on a Dynatech Microelisa reader at a wavelength of 570 nm.
Determination of LP-BM5 titers in spleen homogenates. Virus titers in the supernatants of 10% spleen homogenates were determined by a focal immunoassay based on the method of Chesebro and Wehrly (3) Treatment of opportunistic HSV-1 infections in mice immunosuppressed by LP-BM5 virus infection. LP-BM5-immunosuppressed mice were susceptible to experimental infection with HSV-1 2 months after their initial retrovirus infection, whereas immunocompetent littermates were fully resistant.
Acyclovir (Fig. 1) and PMEA (Fig. 2) were equally effective in prolonging the mean survival time of immunosuppressed mice experimentally infected (intraperitoneally) with a neurovirulent strain of HSV-1 (McIntyre) that ultimately disseminated to the brain; however, ribavirin was inactive against this infection (Fig. 1) . PMEA was also highly effective in the treatment of pulmonary HSV-1 infections (Fig. 3) .
DISCUSSION
Few animal models exist that are useful for evaluating antiviral agents that may be effective in the treatment of human AIDS. Most of the animal models (primate, bovine, or feline) considered relevant are too expensive for routine drug evaluation and too difficult to handle and maintain. The MAIDS model offers the advantage of being inexpensive and easy to handle. The classical AIDS drug AZT was quite effective in controlling virus replication and immunosuppression when therapy was initiated on the day of LP-BM5 virus infection. In contrast, AZT was not effective when given to mice with established disease (23 days postinfection). Thus, our observations on the therapeutic effects of AZT in MAIDS are similar to those with AZT in human AIDS (4) and in other murine retroviral models (23) .
Both in vitro and in vivo antiretroviral and antiherpesviral activities of PMEA have been reported (1, 5-7). The present study has used the MAIDS model to demonstrate that PMEA was as effective as AZT in delaying immunosuppression, as evidenced by the increased resistance to HSV-1 superinfection. Like AZT, PMEA was not effective in reversing or slowing the course of established disease.
We previously reported the synergistic response observed when rhuIFNalpha-B/D was used with AZT in the treatment of MAIDS (8) . In this study, rhuIFNalpha-B/D used in combination with PMEA was more effective than either drug alone when administered late in the course of MAIDS. Although the mechanism by which rhuIFNalpha-B/D complements PMEA is not clear, it is quite likely that both drugs exert their virustatic effects at different points in the viral replicative pathway. Thus PMEA may interfere with the synthesis of viral nucleic acid, whereas interferon may augment immune surveillance and induce the synthesis of cellular proteins that inhibit viral replication.
As a consequence of the marked immunosuppression caused by infection with LP-BM5 virus, mice develop susceptibility to experimental superinfection with HSV-1 (8) or ectromelia virus (2) . This feature has allowed us to determine the efficacy of PMEA against opportunistic infections in immunocompromised mice. Both PMEA and acyclovir afforded mice a significant degree of protection to infection with the McIntyre strain of HSV-1, whereas ribavirin was inactive. PMEA was also effective against the VR3 strain. underlying retroviral cause of immunosuppression. This feature of PMEA may be of great value in view of the observation that herpesviruses may act as cofactors in the onset and progression of human AIDS (16) .
Although a number of disease parameters (e.g., spleen weight, mitogenic response of splenocytes, viral titers, and susceptibility to superinfection) have been used to monitor drug efficacy in the MAIDS model, it is difficult to conclude which parameter is the most relevant. For instance, we previously reported (8) that AZT treatment protects against HSV-1 superinfection but produces only a slight enhancement of mitogenic response of splenocytes, similar to that observed in the current study. The lack of an effect of AZT on mitogen responses may be due to the drug itself being toxic to lymphocyte subpopulations that are responsive to ConA. Alternatively, diminished ConA responses may be caused by virus-induced proteins not associated with infectious virus. Nonetheless, the fact that death in AIDS patients usually results from opportunistic infections suggests that resistance to superinfection may be the most important determinant of drug efficacy.
In conclusion, this study has demonstrated the value of the broad-spectrum antiviral agent PMEA on both early retroviral replication and opportunistic infections that appear late in the course of immunosuppression. Moreover, our data support the concept that the MAIDS model, in combination with experimentally induced bacterial or viral superinfection, provides a suitable alternative to drug evaluation in more expensive and less convenient animal models of retrovirus-induced immunosuppression.
